

31 May 2013

TENDER RESULTS

PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2012/13 Invitation to Tender, dated 31 October 2012 and the 2011/12 Invitation to Tender, dated 01 November 2011.

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the **12th of the month prior to the date of subsidy change**. More information and NOPC forms can be found on our website – <http://www.pharmac.health.nz/medicines/how-medicines-are-funded/new-funding-applications/pharmaceutical-product-specifications-the-change-process>

Where a product does not have a current Pharmacode, suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand before the 12th of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

2011/12 Tender – Sole Subsidised Supply Status and Hospital Supply Status applies until 30 June 2015

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current subsidy and (price)	New subsidy and price	Sole supply brand (Supplier)	Date of listing/subsidy change for tender winning brand	Date of reference pricing of other listed brands	Sole Subsidised Supply date (and delisting of other listed brands)	Brand (Supplier) affected by reference pricing and delisting
Oxycodone hydrochloride*	Tab controlled-release 10 mg; 20 tablet bottle	\$11.14	\$6.75	Oxydone BNM (InterPharma)	1 August 2013	1 October 2013	1 January 2014	OxyContin (Mundipharma)
Oxycodone hydrochloride*	Tab controlled-release 20 mg; 20 tablet bottle	\$18.93	\$11.50	Oxydone BNM (InterPharma)	1 August 2013	1 October 2013	1 January 2014	OxyContin (Mundipharma)
Oxycodone hydrochloride*	Tab controlled-release 40 mg; 20 tablet bottle	\$33.29	\$18.50	Oxydone BNM (InterPharma)	1 August 2013	1 October 2013	1 January 2014	OxyContin (Mundipharma)
Oxycodone hydrochloride*	Tab controlled-release 80 mg; 20 tablet bottle	\$58.03	\$34.00	Oxydone BNM (InterPharma)	1 August 2013	1 October 2013	1 January 2014	OxyContin (Mundipharma)

*A brand switch fee of \$4.33 is payable for this product from 1 January 2014 until 1 February 2014

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

2. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of listing/price change for tender winning brand	Hospital Supply Status date (and delisting of other listed brands)	Brand (Supplier) to be delisted
Oxycodone hydrochloride	Tab controlled-release 10 mg; 20 tablet bottle	\$11.14	\$6.75	Oxydone BNM (InterPharma)	1%	1 August 2013	1 October 2013	OxyContin (Mundipharma)
Oxycodone hydrochloride	Tab controlled-release 20 mg; 20 tablet bottle	\$18.93	\$11.50	Oxydone BNM (InterPharma)	1%	1 August 2013	1 October 2013	OxyContin (Mundipharma)

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of listing/price change for tender winning brand	Hospital Supply Status date (and delisting of other listed brands)	Brand (Supplier) to be delisted
Oxycodone hydrochloride	Tab controlled-release 40 mg; 20 tablet bottle	\$33.29	\$18.50	Oxydone BNM (InterPharma)	1%	1 August 2013	1 October 2013	OxyContin (Mundipharma)
Oxycodone hydrochloride	Tab controlled-release 80 mg; 20 tablet bottle	\$58.03	\$34.00	Oxydone BNM (InterPharma)	1%	1 August 2013	1 October 2013	OxyContin (Mundipharma)

2012/13 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2016

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current subsidy and (price)	New subsidy and price	Sole supply brand (Supplier)	Date of listing/subsidy change for tender winning brand	Date of reference pricing of other listed brands	Sole Subsidised Supply date (and delisting of other listed brands)	Brand (Supplier) affected by reference pricing and delisting
Clopidogrel	Tab 75 mg; 84 tablet blister pack	\$16.25 per 90 tablets	\$5.48 per 84 tablets	Arrow – Clopid (Arrow)	1 October 2013	1 December 2013	1 March 2014	Apo-Clopidogrel (Apotex)
Compound electrolytes	Powder for oral soln; 10 sachets	\$1.12 per 5 sachets	\$1.80 per 10 sachets	Enerlyte (Multichem)	1 December 2013	1 February 2014	1 May 2014	Electral (Arrow)
Loratadine	Tab 10 mg; 100 tablet blister pack	\$2.09	\$1.30	Lorafix (Arrow)	1 October 2013	1 December 2013	1 March 2014	Loraclear Hayfever Relief (AFT)
Mycophenolate mofetil*	Cap 250 mg; 100 capsule blister pack	\$70.00 per 100 capsules (Roche) \$60.00 per 100 capsules (Douglas) \$30.00 per 50 capsules (Mylan)	\$25.00 per 100 capsules	CellCept (Roche)	1 September 2013	1 November 2013	1 February 2014	Myaccord (Douglas) Ceptolate (Mylan)
Mycophenolate mofetil*	Tab 500 mg; 50 tablet blister pack	\$70.00 per 50 tablets (Roche) \$60.00 per 50 tablets (Douglas/Mylan)	\$25.00 per 50 tablets	CellCept (Roche)	1 September 2013	1 November 2013	1 February 2014	Myaccord (Douglas) Ceptolate (Mylan)
Ropinirole hydrochloride	Tab 0.25 mg; 100 tablet blister pack	\$6.20 per 84 tab	\$2.36 per 100 tab	Apo-Ropinirole (Apotex)	1 December 2013	1 February 2014	1 May 2014	Ropin (Mylan)

*Brand switch fee of \$4.33 is payable for this product from 1 February 2014 until 1 May 2014

Chemical Name	Presentation; Pack size and type	Current subsidy and (price)	New subsidy and price	Sole supply brand (Supplier)	Date of listing/subsidy change for tender winning brand	Date of reference pricing of other listed brands	Sole Subsidised Supply date (and delisting of other listed brands)	Brand (Supplier) affected by reference pricing and delisting
Ropinirole hydrochloride	Tab 1 mg; 100 tablet blister pack	\$15.95 per 84 tab	\$5.32 per 100 tab	Apo-Ropinirole (Apotex)	1 December 2013	1 February 2014	1 May 2014	Ropin (Mylan)
Ropinirole hydrochloride	Tab 2 mg; 100 tablet blister pack	\$24.95 per 84 tab	\$7.72 per 100 tab	Apo-Ropinirole (Apotex)	1 December 2013	1 February 2014	1 May 2014	Ropin (Mylan)
Ropinirole hydrochloride	Tab 5 mg; 100 tablet blister pack	\$38.00 per 84 tab	\$14.48 per 100 tab	Apo-Ropinirole (Apotex)	1 December 2013	1 February 2014	1 May 2014	Ropin (Mylan)

2. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current subsidy and (price)	New subsidy and price	Sole supply brand (Supplier)	Date of subsidy change	Sole Subsidised Supply date
Cefaclor	Cap 250 mg; 100 capsule bottle	\$24.57	\$26.00	Ranbaxy-Cefaclor (Douglas)	1 October 2013	1 January 2014
Cefaclor	Grans for oral liq 125 mg per 5 ml; 100 ml bottle	\$3.53	\$3.53	Ranbaxy-Cefaclor (Douglas)	1 October 2013	1 January 2014
Fusidic acid	Oint 2 %; 15 g OP tube	\$3.25	\$3.45	Foban (AFT)	1 July 2013	1 October 2013
Gemfibrozil	Tab 600 mg; 60 tablet bottle	\$14.00	\$17.60	Lipazil (Douglas)	1 September 2013	1 December 2013
Hydrocortisone	Inj 100 mg vial; 1 vial	\$3.99	\$4.99	Solu-Cortef (Pfizer)	1 August 2013	1 November 2013
Ispaghula (psyllium) husk	Powder for oral soln; 500 g OP bottle	\$6.02	\$5.51	Konsyl-D (Mylan)	1 July 2013	1 October 2013
Lactulose	Oral liq 10 g per 15 ml; 500 ml bottle	\$7.68 per 1,000 ml ¹	\$3.84 per 500 ml	Laevolac (Douglas)	1 November 2013	1 May 2014

¹ Douglas' 1,000 ml pack size of Laevolac will be delisted from Section B of the Pharmaceutical Schedule on 1 May 2014
A599686590547 - qA25122

Chemical name	Presentation; Pack size and type	Current subsidy and (price)	New subsidy and price	Sole supply brand (Supplier)	Date of subsidy change	Sole Subsidised Supply date
Morphine tartrate	Inj 80 mg per ml, 1.5 ml ampoule; 5 ampoules	\$30.00	\$35.60	Hospira (Hospira)	1 July 2013	1 October 2013
Morphine tartrate	Inj 80 mg per ml, 5 ml ampoule; 5 ampoules	\$75.00	\$107.67	Hospira (Hospira)	1 July 2013	1 October 2013
Pindolol	Tab 5 mg; 100 tablet bottle	\$5.40	\$9.72	Apo-Pindolol (Apotex)	1 September 2013	1 December 2013
Pindolol	Tab 10 mg; 100 tablet bottle	\$9.19	\$15.62	Apo-Pindolol (Apotex)	1 September 2013	1 December 2013
Pindolol	Tab 15 mg; 100 tablet bottle	\$13.80	\$23.46	Apo-Pindolol (Apotex)	1 September 2013	1 December 2013
Sodium chloride	Inj 23.4%, 20 ml ampoule; 5 ampoules	\$31.25	\$31.25	Biomed (Biomed)	1 July 2013	1 October 2013
Sulphasalazine	Tab 500 mg; 100 tablet bottle	\$11.68	\$11.68	Salazopyrin (Pfizer)	1 August 2013	1 November 2013
Sulphasalazine	Tab EC 500 mg; 100 tablet bottle	\$12.89	\$12.89	Salazopyrin-EN (Pfizer)	1 August 2013	1 November 2013
Sumatriptan	Tab 50 mg; ² 100 tablet bottle	\$38.83 per 100 tablets	\$29.80 per 100 tablets	Arrow-Sumatriptan (Arrow)	1 July 2013	1 October 2013
Sumatriptan	Tab 100 mg; ³ 100 tablet bottle	\$77.66 per 100 tablets	\$54.80 per 100 tablets	Arrow-Sumatriptan (Arrow)	1 July 2013	1 October 2013
Sumatriptan	Inj 12 mg per ml, 0.5 ml cartridge; 2 OP syringes	\$36.00	\$13.80	Arrow-Sumatriptan (Arrow)	1 July 2013	1 October 2013
Timolol	Eye drops 0.25%, gel forming; 2.5 ml OP bottle	\$3.30	\$3.30	Timoptol XE (MSD)	1 January 2014	1 April 2014

² The price and subsidy of Arrow's 4 tablet pack size will be amended to \$1.19 from 1 July 2013 and this pack size will be delisted from 1 October 2013

³ The price and subsidy of Arrow's 2 tablet pack size will be amended to \$1.10 from 1 July 2013 and this pack size will be delisted from 1 October 2013

Chemical name	Presentation; Pack size and type	Current subsidy and (price)	New subsidy and price	Sole supply brand (Supplier)	Date of subsidy change	Sole Subsidised Supply date
Timolol	Eye drops 0.5%, gel forming; 2.5 ml OP bottle	\$3.78	\$3.78	Timoptol XE (MSD)	1 January 2014	1 April 2014
Tretinoin	Crn 0.5 mg per g; 50 g OP tube	\$13.90	\$13.90	ReTrieve (Valeant)	1 July 2013	1 October 2013
Zidovudine [AZT]	Cap 100 mg; 100 capsule bottle	\$145.00	\$152.25	Retrovir (GSK)	1 August 2013	1 November 2013
Zidovudine [AZT]	Oral liq 10 mg per ml; 200 ml OP bottle	\$29.00	\$30.45	Retrovir (GSK)	1 August 2013	1 November 2013

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

3. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of listing/price change for tender winning brand	Hospital Supply Status date (and delisting of other listed brands)	Brand (Supplier) to be delisted
Clopidogrel	Tab 75 mg; 84 tablet blister pack	\$16.25 per 90 tablets	\$5.48 per 84 tablets	Arrow – Clopid (Arrow)	1%	1 October 2013	1 December 2013	Apo-Clopidogrel (Apotex)
Loratadine	Tab 10 mg; 100 tablet blister pack	\$2.09	\$1.30	Lorafix (Arrow)	1%	1 October 2013	1 December 2013	Loraclear Hayfever Relief (AFT)
Mycophenolate mofetil	Cap 250 mg; 100 capsule blister pack	\$70.00 per 100 capsules (Roche) \$60.00 per 100 capsules (Douglas) \$30.00 per 50 capsules (Mylan)	\$25.00 per 100 capsules	CellCept (Roche)	1%	1 September 2013	1 November 2013	Myaccord (Douglas) Ceptolate (Mylan)

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of listing/price change for tender winning brand	Hospital Supply Status date (and delisting of other listed brands)	Brand (Supplier) to be delisted
Mycophenolate mofetil	Tab 500 mg; 50 tablet blister pack	\$70.00 per 50 tablets (Roche) \$60.00 per 50 tablets (Douglas/Mylan)	\$25.00 per 50 tablets	CellCept (Roche)	1%	1 September 2013	1 November 2013	Myaccord (Douglas) Ceptolate (Mylan)
Ropinirole hydrochloride	Tab 0.25 mg; 100 tablet blister pack	\$6.20 per 84 tab	\$2.36 per 100 tab	Apo-Ropinirole (Apotex)	1%	1 December 2013	1 February 2014	Ropin (Mylan)
Ropinirole hydrochloride	Tab 1 mg; 100 tablet blister pack	\$15.95 per 84 tab	\$5.32 per 100 tab	Apo-Ropinirole (Apotex)	1%	1 December 2013	1 February 2014	Ropin (Mylan)
Ropinirole hydrochloride	Tab 2 mg; 100 tablet blister pack	\$24.95 per 84 tab	\$7.72 per 100 tab	Apo-Ropinirole (Apotex)	1%	1 December 2013	1 February 2014	Ropin (Mylan)
Ropinirole hydrochloride	Tab 5 mg; 100 tablet blister pack	\$38.00 per 84 tab	\$14.48 per 100 tab	Apo-Ropinirole (Apotex)	1%	1 December 2013	1 February 2014	Ropin (Mylan)

4. Tenders awarded to listed pharmaceuticals where only the current brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of price change	Hospital Supply Status date
Cefaclor	Cap 250 mg; 100 capsule bottle	\$24.57	\$26.00	Ranbaxy-Cefaclor (Douglas)	1%	1 October 2013	1 December 2013
Cefaclor	Grans for oral liq 125 mg per 5 ml; 100 ml bottle	\$3.53	\$3.53	Ranbaxy-Cefaclor (Douglas)	1%	1 October 2013	1 December 2013
Fusidic acid	Oint 2 %; 15 g tube	\$3.25	\$3.45	Foban (AFT)	1%	1 July 2013	1 September 2013
Gemfibrozil	Tab 600 mg; 60 tablet bottle	\$14.00	\$17.60	Lipazil (Douglas)	1%	1 September 2013	1 November 2013
Hydrocortisone	Inj 100 mg vial; 1 vial	\$3.99	\$4.99	Solu-Cortef (Pfizer)	1%	1 August 2013	1 October 2013

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of price change	Hospital Supply Status date
Ispaghula (psyllium) husk	Powder for oral soln; 500 g bottle	\$6.02	\$5.51	Konsyl-D (Mylan)	1%	1 July 2013	1 September 2013
Lactulose	Oral liq 10 g per 15 ml; 500 ml bottle	\$7.68 per 1,000 ml ⁴	\$3.84 per 500 ml	Laevolac (Douglas)	1%	1 November 2013	1 May 2014 ⁵
Morphine tartrate	Inj 80 mg per ml, 1.5 ml ampoule; 5 ampoules	\$30.00	\$35.60	Hospira (Hospira)	1%	1 July 2013	1 September 2013
Morphine tartrate	Inj 80 mg per ml, 5 ml ampoule; 5 ampoules	\$75.00	\$107.67	Hospira (Hospira)	1%	1 July 2013	1 September 2013
Mycophenolate mofetil	Inj 500 mg vial; 4 vials	\$133.33	\$133.33	CellCept (Roche)	1%	1 September 2013	1 November 2013
Mycophenolate mofetil	Powder for oral liq 1 g per 5 ml; 165 ml bottle	\$285.00	\$187.25	CellCept (Roche)	1%	1 September 2013	1 November 2013
Ondansetron	Inj 2 mg per ml, 2 ml ampoule; 5 ampoules	\$2.64	\$1.82	Ondanaccord (Arrow)	1%	1 July 2013	1 September 2013
Ondansetron	Inj 2 mg per ml, 4 ml ampoule 5 ampoules	\$2.98	\$2.18	Ondanaccord (Arrow)	1%	1 July 2013	1 September 2013
Pindolol	Tab 5 mg; 100 tablet bottle	\$5.40	\$9.72	Apo-Pindolol (Apotex)	1%	1 September 2013	1 November 2013
Pindolol	Tab 10 mg; 100 tablet bottle	\$9.19	\$15.62	Apo-Pindolol (Apotex)	1%	1 September 2013	1 November 2013
Pindolol	Tab 15 mg; 100 tablet bottle	\$13.80	\$23.46	Apo-Pindolol (Apotex)	1%	1 September 2013	1 November 2013
Piperacillin sodium with tazobactam sodium	Inj 4 g with tazobactam sodium 500 mg; 1 vial	\$12.00	\$5.84	Tazocin EF (Pfizer)	1%	1 August 2013	1 October 2013

⁴ Douglas' 1,000 ml pack size of Laevolac will be delisted from Part II of Section H of the Pharmaceutical Schedule on 1 May 2014

⁵ Please note correction

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of price change	Hospital Supply Status date
Sodium chloride	Inj 23.4%, 20 ml ampoule; 5 ampoules	\$31.25	\$31.25	Biomed (Biomed)	1%	1 July 2013	1 September 2013
Sulphasalazine	Tab 500 mg; 100 tablet bottle	\$11.68	\$11.68	Salazopyrin (Pfizer)	1%	1 August 2013	1 October 2013
Sulphasalazine	Tab EC 500 mg; 100 tablet bottle	\$12.89	\$12.89	Salazopyrin-EN (Pfizer)	1%	1 August 2013	1 October 2013
Sumatriptan	Tab 50 mg; 100 tablet bottle	\$38.83	\$29.80	Arrow-Sumatriptan (Arrow)	1%	1 July 2013	1 September 2013
Sumatriptan	Tab 100 mg; 100 tablet bottle	\$77.66	\$54.80	Arrow-Sumatriptan (Arrow)	1%	1 July 2013	1 September 2013
Sumatriptan	Inj 12 mg per ml, 0.5 ml cartridge; 2 syringes	\$36.00	\$13.80	Arrow-Sumatriptan (Arrow)	1%	1 July 2013	1 September 2013
Timolol	Eye drops 0.25%, gel forming; 2.5 ml bottle	\$3.30	\$3.30	Timoptol XE (MSD)	1%	1 January 2014	1 March 2014
Timolol	Eye drops 0.5%, gel forming; 2.5 ml bottle	\$3.78	\$3.78	Timoptol XE (MSD)	1%	1 January 2014	1 March 2014
Zidovudine [AZT]	Cap 100 mg; 100 capsule bottle	\$145.00	\$152.25	Retrovir (GSK)	1%	1 August 2013	1 October 2013
Zidovudine [AZT]	Oral liq 10 mg per ml; 200 ml bottle	\$29.00	\$30.45	Retrovir (GSK)	1%	1 August 2013	1 October 2013

Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2012/13 Invitation to Tender, dated 31 October 2012:

Chemical Name	Line Item	Chemical Name	Line Item
Adapalene	Crn 0.1%	Glycerol	Liq BP
Adapalene	Gel 0.1%	Malathion	Liq 0.5%
Captopril	Tab 12.5 mg	Malathion	Shampoo 1%
Captopril	Tab 25 mg	Ondansetron	Tab disp 4 mg
Captopril	Tab 50 mg	Ondansetron	Tab disp 8 mg
Fexofenadine Hydrochloride	Tab 120 mg	Pregnancy Tests - HCG Urine	Urine diagnostic test
Fexofenadine Hydrochloride	Tab 180 mg	Psyllium husk	Powder/granules - sugar free
Fexofenadine Hydrochloride	Tab 60 mg	Senna	Tab standardised

For products included in the 2011/12 Invitation to Tender or the 2012/13 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.